About SanBio
SanBio is a publicly listed company based in Tokyo (Japan) founded in 2001. Regenerative cell medicines for neurological disorders are developed. The company has 29 employees. Its website sanbio.com draws about 34 thousand monthly visits. Its focus areas include Life Sciences, Cell Therapy, Stem Cells and Progenitor Cells.
Company details
SanBio is focused on regenerative cell medicines for neurological disorders such as stroke, traumatic brain injury, diseases of the eye, and Parkinsons disease. Its lead drug SB643 is being developed for the treatment of Stroke and Traumatic Brain Injury (Phase 2). SB643 is a modified bone marrow-derived mesenchymal stem cells - SanBio. SB623 is also being developed for the treatment of Parkinsons, Alzheimers, Spinal cord injury (preclinical). Other preclinical drugs programs are for peripheral nerve damage and muscular dystrophy.
- Headquarters Tokyo, Japan
- Employees 29
- Stage Public
- SectorsHealthcare
- Website category Finance · Investing
- Email••••••••
- Phone•••• ••••
- Website sanbio.com
- Social LinkedIn
- Legal Name Sanbio Co., Ltd.
- Net Profit-$24.93 M (USD)-33.29as on Jan 31, 2026
- EBITDA-$24.61 M (USD)-7.99as on Jan 31, 2026
- Latest Funding Round$20M (USD), Grant
Jul 2017
- Investors
- Employee Count29
Funding Insights of SanBio
- Total Rounds 1
- Last Round Grant — $20M
- First Round $20M
(Jul 2017)
- Investors Count 1
All 1 funding rounds of SanBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2017 | $20M | Grant | – | – |
1 investors in total: 1 institutional.
Investors in SanBio
SanBio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include CIRM.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| cirm.ca.gov |
Investor details for SanBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of SanBio
SanBio is a publicly listed company on the TSE with ticker symbol 4592 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Apr 2015
- Listed onTSE: 4592
- Listed entitySanBio Co., Ltd.
- Exchange sectorHealth technology
- ISINJP3336750009
- Share price995.00 JPY (-3.96% on the day) · 2026-10-14
- Market capitalisation80,868,797,974.00 JPY
- EPS (diluted, trailing year)-47.71 JPY
- Volume (last session)1,998,800
Financials of SanBio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -3.84B JPY | -3.79B JPY | |
| 2024 | -2.88B JPY | -3.51B JPY | |
| 2023 | -2.64B JPY | -4.53B JPY | |
| 2022 | -5.56B JPY | -7.87B JPY | |
| 2021 | -4.68B JPY | -6.49B JPY |
Detailed financial statements for SanBio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of SanBio
3 dated milestones of SanBio across 16 years, from founding to its latest funding, stage changes and deals.
- Founded SanBio is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $20.0M.
Web traffic of SanBio
The website of SanBio (sanbio.com) receives about 34.4K visits a month and ranks #579,652 among all websites worldwide, #5,750 in Investing.
- Monthly visits34.4K
▼ 39.5% vs previous month
- Unique visitors13.1K
per month
- Global rank#579,652
among all websites
- Category rank#5,750
Finance · Investing
- Bounce rate44%
- Pages per visit2.9
- Average visit2 min 33 sec
- DevicesDesktop 61% · Mobile 39%
Websites whose visitors overlap most with SanBio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| rakuten-sec.co.jp | 100% | 94.2M | #325 | View details | |
kabutan.jp | kabutan.jp | 98% | #2,472 | – | |
finance.yahoo.co.jp | finance.yahoo.co.jp | 97% | #530 | – | |
bridge-salon.jp | bridge-salon.jp | 92% | #181,928 | – | |
| minkabu.jp | 91% | 16.4M | #3,198 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for SanBio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sanbio
Complete news archive for SanBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SanBio
SanBio was founded in 2001 and raised its 1st funding round 16 years after it was founded.
SanBio is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
SanBio has 29 employees.
SanBio is focused on regenerative cell medicines for neurological disorders such as stroke, traumatic brain injury, diseases of the eye, and Parkinsons disease. Its lead drug SB643 is being developed for the treatment of Stroke and Traumatic Brain Injury (Phase 2). SB643 is a modified bone marrow-derived mesenchymal stem cells - SanBio. SB623 is also being developed for the treatment of Parkinsons, Alzheimers, Spinal cord injury (preclinical). Other preclinical drugs programs are for peripheral nerve damage and muscular dystrophy.
Yes, SanBio is publicly traded on TSE under the ticker symbol 4592.
SanBio has 1 investor. Key investors include CIRM.